

7/16/07

PTO/SB/08a (03-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		09787461
	Filing Date		2001-03-02
	First Named Inventor	Esteban Cvikovich	
	Art Unit	1614	
	Examiner Name	Phyllis G. Spivack	
Attorney Docket Number		13566.105002	

U.S. PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					
If you wish to add additional U.S. Patent citation information please click the Add button.						
U.S. PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
PS	1	20060030571	A1	2006-02-09	Rinehart et al.	
PS	2	20070082856	A1	2007-04-12	Gianni et al.	
PS	3	20070128201	A1	2007-06-07	D'Incalci et al.	
PS	4	20060094687	A1	2006-04-04	Beijnen et al.	
PS	5	20070004691	A1	2007-01-04	Donald et al.	
If you wish to add additional U.S. Published Application citation information please click the Add button.						
FOREIGN PATENT DOCUMENTS						

Phyllis Spivack 11/4/07

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		09787461
Filing Date		2001-03-02
First Named Inventor	Esteban Cvitkovich	
Art Unit	1614	
Examiner Name	Phyllis G. Spivack	
Attorney Docket Number	13566.105002	

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
PS	1	WO 2005/049030	WO	A1	2005-06-02	Rowinsky et al.		<input type="checkbox"/>
PS	2	WO 2005/049031	WO	A1	2005-06-02	Rybak		<input type="checkbox"/>
PS	3	WO 2006/046080	WO	A1	2006-05-04	Gilles et al.		<input type="checkbox"/>
PS	4	WO 2002/36135	WO	A1	2002-05-10	Takahashi et al.		<input type="checkbox"/>
PS	5	WO 2000/69441	WO	A1	2000-11-23	Cvitkovich et al.		<input type="checkbox"/>
PS	6	WO 2006/035244	WO	A1	2006-04-06	Allavena et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
PS	1	McMeekin, D.S. et al., "Final results of a phase II study of weekly trabectedin in second/third line ovarian carcinoma," Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, Vol. 23, No. 16S, Part 1 of 11 (June 1 Supplement), Abstract No. 5011, May 13-17, 2005.	<input type="checkbox"/>
PS	2	Twelves et al., "Phase I clinical and pharmacokinetic (PK) study of ecteinascidin-743 (ET-743) given as a one hour infusion every 21 days," 1998 ASCO Annual Meeting Proceedings, Abstract No. 889, 1998	<input type="checkbox"/>

Phyllis Spivack

11/4/07

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09787461
Filing Date	2001-03-02
First Named Inventor	Esteban Cvitkovich
Art Unit	1614
Examiner Name	Phyllis G. Spivack
Attorney Docket Number	13566.105002

PS	3	Bowman, A. et al., "Phase I clinical and pharmacokinetic (PK) study of ecteinascidin-743 (ET-743) given as a one hour infusion every 21 days," Annals Oncology, Abstract 452, 1998.	<input type="checkbox"/>
PS	4	Hendriks, H.R. et al., "High antitumor activity of ET743 against human tumor xenografts from melanoma, non-small-cell lung and ovarian cancer," Annals of Oncology, vol. 10, pages 1233-1240, 1999.	<input type="checkbox"/>
PS	5	Michaelson, M.D. et al., "Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC)," Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, Vol. 23, No. 16S, Part I of II (June 1 Supplement), Abstract No. 4517, May 13- 17, 2005.	<input type="checkbox"/>
PS	6	Taamma, A. et al., "Ecteinascidin-743 (ET-743) 24 hours continuous infusion (CI): clinical and pharmacokinetic phase I study in solid tumor patients (PTS). Preliminary Results" 1998 ASCO Annual Meeting Proceedings, Abstract No. 890, 1998.	<input type="checkbox"/>
	7	Villalona-Calero, M. et al., "A phase I and pharmacokinetic study of ET-743, a novel DNA minor groove binder of marine origin, administered as a 1-hour infusion daily x 5 days," Annals Oncology, Abstract 453, 1998.	<input type="checkbox"/>
PS	8	Riofrio, M. et al., "Ecteinascidin-743 (ET-743) 24 hours continuous infusion (CI): Clinical and pharmacokinetic phase I study progressive report," 23rd European Society for Medical Oncology Congress, Abstract 639P, November 6-10, 1998.	<input type="checkbox"/>
PS	9	Ghielmini, M. et al., "In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743)," Annals of Oncology, vol. 9, pages 989-993, 1998.	<input type="checkbox"/>
PS	10	Cvitkovic, E. et al., "Ecteinascidin-743 (ET-743) 24 hour continuous intravenous infusion (CI) phase I study in solid tumors (ST) patients," Annals Oncology, Abstract 456, 1998.	<input type="checkbox"/>
PS	11	Jimeno, J.M. et al., "Enhancing the preclinical in vivo antitumor activity of ecteinascidin 743, a marine natural product currently in phase II clinical trials," Proceedings of the 1999 AACR-NCI-EORTC International Conference, Clinical Cancer Research, Volume 5, Abstract No. 306, November 1999.	<input type="checkbox"/>
PS	12	Hillebrand, M.J.X. et al., "Pharmacokinetics of ecteinascidin-743 (ET-743) in three phase I studies," Annals Oncology, Abstract No. 455, 1998.	<input type="checkbox"/>
PS	13	Cvitkovic, E. et al., "Final results of a phase I study of ecteinascidin-743 (ET-743) 24 hour (h) continuous infusion (CI) in advanced solid tumors (AST) patients (pts)," 1999 ASCO Annual Meeting Proceedings, Abstract No. 690, 1999.	<input type="checkbox"/>

P. Spivack 11/4/07

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	09787461
Filing Date	2001-03-02
First Named Inventor	Esteban Cvilkovich
Art Unit	1614
Examiner Name	Phyllis G. Spivack
Attorney Docket Number	13566.105002

Ps	14	Forouzes, B. et al., "Phase I and pharmacokinetic study of the marine-derived DNA minor groove binder ET- 743 on a weekly x3 every-4-week schedule in patients with advanced solid malignancies," Proceedings of the 2001 AACR-NCI-EORTC International Conference, Abstract No. 209, October 29-November 2, 2001 .	<input type="checkbox"/>
Ps	15	Ghielmini, M. et al., "Schedule-dependent myelotoxicity induced in vitro by the new marine derived minor groove interacting agent ecteinascidin 743," ECCO, vol. 9, Abstract No. 807, September 17, 1997.	<input type="checkbox"/>
Ps	16	Taamma, A. et al., "Phase I clinical study of ecteinascidin-743 (ET-743) as a 24 hours continuous intravenous infusion (CI) in patients (pts) with solid tumors (st): A progress report," ECCO, vol. 9, Abstract No. 1119, September 18, 1997	<input type="checkbox"/>
Ps	17	Barrera, H. et al., "Interaction of ET-743 and standard cytotoxic agents against a panel of human tumor cell lines," Proceedings of the American Association for Cancer Research, Volume 40, page 591, Abstract No. 3896, March, 1999.	<input type="checkbox"/>
Ps	18	Fourouzes, B. et al., "Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder, administered weekly to patients with advanced cancer," Proc Am Soc Clin Oncol, vol 20, 2001 ASCO Annual Meeting Proceedings, Abstract No. 373, 2001.	<input type="checkbox"/>
Ps	19	Garcia Gravalos, M.D., et al., "In vitro schedule-dependent cytotoxicity by ecteinascidin 743 (ET-743) against human tumor cells," 23rd European Society for Medical Oncology Congress, Abstract No. 652, November 6- 10, 1998 .	<input type="checkbox"/>
Ps	20	Hidalgo, M., et al., "A phase I and pharmacokinetic (PK) study of ET-743, a novel minor groove binder of marine origin administered on a daily x 5 schedule," 23rd European Society for Medical Oncology Congress, Abstract No. 613P, November 6-10, 1998 .	<input type="checkbox"/>
Ps	21	Drugs Fut., "Ecteinascidin-743" vol. 22, no. 11, page 1279, 1997 .	<input type="checkbox"/>
Ps	22	Forouzes, B., et al., "Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder, administered weekly to patients with advanced cancer," European Journal of Cancer, ECCO 11, volume 37, supplement 6, Abstract No. 106, October 21-25, 2001 .	<input type="checkbox"/>
Ps	23	Valoti, G., et al., "Ecteinascidin-743 (ET-743), a marine natural compound, shows antitumor activity against human ovarian carcinoma xenografts," European J. of Cancer, vol. 34(2), page S39, Abstract PP179, 1998 .	<input type="checkbox"/>
Ps	24	Jimeno, J. et al., "Phase I and pharmacokinetic (PK) study of Et-743, a novel minor groove binder of marine origin on a daily [times] 5 schedule," 1998 ASCO Annual Meeting Proceedings, Abstract No. 737, 1998 .	<input type="checkbox"/>

P. Spivack 11/4/07

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		09787461
	Filing Date		2001-03-02
	First Named Inventor	Esteban Cvitkovich	
	Art Unit	1614	
	Examiner Name	Phyllis G. Spivack	
Attorney Docket Number		13566.105002	

PS	25	Villaiona-Calero, M. et al., "Final results of a Phase I and pharmacokinetic (PK) study of the marine minor groove binder ET-743 on a daily x 5 schedule," 1999 ASCO Annual Meeting Proceedings, Abstract No. 691, 1999 .	<input type="checkbox"/>
PS	26	Gurtler, J.S. et al., "Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration regimens," Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, vol. 23, no. 16S, part I of II (June 1 Supplement), Abstract No. 625, 2005 .	<input type="checkbox"/>
PS	27	Twelves, C.J. et al., "Phase I and pharmacokinetic study of ecteinascidin-743 (ET-743) given as a one hour infusion every 21 days," ECCO, vol. 9, Abstract No. 1107, September 18, 1997	<input type="checkbox"/>
PS	28	Izbicka, E. et al., "In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC- 648766) against human tumors explanted from patients," Annals of Oncology, vol. 9, pages 981-987, 1998 .	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE	
Examiner Signature	Date Considered
<i>P. Spivack</i>	<i>11/4/07</i>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.